ES2996688T3 - Fatty acid derivatives for treating non-alcoholic steatohepatitis - Google Patents
Fatty acid derivatives for treating non-alcoholic steatohepatitis Download PDFInfo
- Publication number
- ES2996688T3 ES2996688T3 ES18833289T ES18833289T ES2996688T3 ES 2996688 T3 ES2996688 T3 ES 2996688T3 ES 18833289 T ES18833289 T ES 18833289T ES 18833289 T ES18833289 T ES 18833289T ES 2996688 T3 ES2996688 T3 ES 2996688T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- mmol
- added
- mixture
- stirred
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title claims abstract description 114
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 title claims abstract description 106
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 223
- 238000011282 treatment Methods 0.000 claims abstract description 97
- 239000013543 active substance Substances 0.000 claims abstract description 28
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims description 259
- 229940126062 Compound A Drugs 0.000 claims description 189
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 189
- 206010016654 Fibrosis Diseases 0.000 claims description 71
- 230000004761 fibrosis Effects 0.000 claims description 66
- VOGXDRFFBBLZBT-AAQCHOMXSA-N 2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(O)=O VOGXDRFFBBLZBT-AAQCHOMXSA-N 0.000 claims description 43
- -1 isopropyl ester Chemical class 0.000 claims description 43
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 20
- 125000004494 ethyl ester group Chemical group 0.000 claims description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 15
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 13
- 239000000556 agonist Substances 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 8
- 238000009097 single-agent therapy Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 claims description 5
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 150000004702 methyl esters Chemical class 0.000 claims description 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 239000006014 omega-3 oil Substances 0.000 claims description 5
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims description 4
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims description 3
- 229940122344 Peptidase inhibitor Drugs 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 abstract description 28
- 208000026594 alcoholic fatty liver disease Diseases 0.000 abstract description 28
- 238000000034 method Methods 0.000 abstract description 19
- 238000011321 prophylaxis Methods 0.000 abstract description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 3
- 229910052760 oxygen Inorganic materials 0.000 abstract description 3
- 239000001301 oxygen Substances 0.000 abstract description 3
- 238000013519 translation Methods 0.000 abstract description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 abstract description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 261
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 235
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 156
- 239000000243 solution Substances 0.000 description 131
- 235000019439 ethyl acetate Nutrition 0.000 description 109
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 102
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 101
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 98
- 230000000694 effects Effects 0.000 description 98
- 238000002360 preparation method Methods 0.000 description 90
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 87
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 87
- 238000005160 1H NMR spectroscopy Methods 0.000 description 83
- 238000003818 flash chromatography Methods 0.000 description 83
- 241000699670 Mus sp. Species 0.000 description 78
- 239000011541 reaction mixture Substances 0.000 description 76
- 239000007832 Na2SO4 Substances 0.000 description 74
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 74
- 229910052938 sodium sulfate Inorganic materials 0.000 description 74
- 235000011152 sodium sulphate Nutrition 0.000 description 74
- 239000003480 eluent Substances 0.000 description 73
- 239000003921 oil Substances 0.000 description 72
- 235000019198 oils Nutrition 0.000 description 72
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 69
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 69
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 66
- 239000012267 brine Substances 0.000 description 64
- 230000002440 hepatic effect Effects 0.000 description 64
- 239000000741 silica gel Substances 0.000 description 64
- 229910002027 silica gel Inorganic materials 0.000 description 64
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 64
- 239000011734 sodium Substances 0.000 description 60
- 235000019253 formic acid Nutrition 0.000 description 56
- 239000012074 organic phase Substances 0.000 description 53
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 48
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 48
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 46
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 45
- 208000019425 cirrhosis of liver Diseases 0.000 description 44
- 230000014509 gene expression Effects 0.000 description 44
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 44
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 43
- 230000002829 reductive effect Effects 0.000 description 43
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 42
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 42
- 210000004185 liver Anatomy 0.000 description 40
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 39
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 239000012299 nitrogen atmosphere Substances 0.000 description 33
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 27
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 27
- 229960002591 hydroxyproline Drugs 0.000 description 27
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 27
- 206010061218 Inflammation Diseases 0.000 description 26
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 26
- 230000004054 inflammatory process Effects 0.000 description 26
- ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 description 26
- 229960001601 obeticholic acid Drugs 0.000 description 26
- 235000005911 diet Nutrition 0.000 description 25
- 229910052757 nitrogen Inorganic materials 0.000 description 25
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 24
- 230000037396 body weight Effects 0.000 description 24
- 230000037213 diet Effects 0.000 description 23
- 239000012044 organic layer Substances 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 23
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 22
- 239000008346 aqueous phase Substances 0.000 description 22
- 239000003814 drug Substances 0.000 description 22
- 108020004999 messenger RNA Proteins 0.000 description 22
- 229960005095 pioglitazone Drugs 0.000 description 22
- 229940079593 drug Drugs 0.000 description 21
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 20
- 239000003112 inhibitor Substances 0.000 description 20
- 102000008186 Collagen Human genes 0.000 description 19
- 108010035532 Collagen Proteins 0.000 description 19
- 235000012000 cholesterol Nutrition 0.000 description 19
- 229920001436 collagen Polymers 0.000 description 19
- 238000003756 stirring Methods 0.000 description 19
- YAQLSKVCTLCIIE-UHFFFAOYSA-N 2-bromobutyric acid Chemical compound CCC(Br)C(O)=O YAQLSKVCTLCIIE-UHFFFAOYSA-N 0.000 description 18
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 18
- 230000007423 decrease Effects 0.000 description 18
- 108010063245 glucagon-like peptide 1 (7-36)amide Proteins 0.000 description 18
- 230000009467 reduction Effects 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 235000009200 high fat diet Nutrition 0.000 description 17
- 239000010410 layer Substances 0.000 description 17
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 description 16
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 description 16
- 206010019708 Hepatic steatosis Diseases 0.000 description 16
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 239000012071 phase Substances 0.000 description 16
- 101150037123 APOE gene Proteins 0.000 description 15
- 102100029470 Apolipoprotein E Human genes 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 15
- 238000011161 development Methods 0.000 description 15
- 230000018109 developmental process Effects 0.000 description 15
- 231100000240 steatosis hepatitis Toxicity 0.000 description 15
- 150000003626 triacylglycerols Chemical class 0.000 description 15
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 13
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 13
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 13
- 206010020880 Hypertrophy Diseases 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 13
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 13
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 13
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 13
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 13
- 150000002632 lipids Chemical class 0.000 description 13
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 13
- 235000019341 magnesium sulphate Nutrition 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 230000007863 steatosis Effects 0.000 description 13
- RIUJWUWLGXBICR-UHFFFAOYSA-N tert-butyl 2-bromobutanoate Chemical compound CCC(Br)C(=O)OC(C)(C)C RIUJWUWLGXBICR-UHFFFAOYSA-N 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 12
- 102100039558 Galectin-3 Human genes 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 239000000090 biomarker Substances 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 238000002565 electrocardiography Methods 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 12
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 11
- 108010082126 Alanine transaminase Proteins 0.000 description 11
- 108010074051 C-Reactive Protein Proteins 0.000 description 11
- 108010001517 Galectin 3 Proteins 0.000 description 11
- 239000012043 crude product Substances 0.000 description 11
- 150000004665 fatty acids Chemical class 0.000 description 11
- 238000013425 morphometry Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 11
- 238000002562 urinalysis Methods 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 10
- 108010011459 Exenatide Proteins 0.000 description 10
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 10
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 229930195729 fatty acid Natural products 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- 230000002757 inflammatory effect Effects 0.000 description 10
- 238000002953 preparative HPLC Methods 0.000 description 10
- 230000000284 resting effect Effects 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 229940086542 triethylamine Drugs 0.000 description 10
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 9
- JILHZKWLEAKYRC-UHFFFAOYSA-N 1-methoxy-2,2-dimethylpropane Chemical compound COCC(C)(C)C JILHZKWLEAKYRC-UHFFFAOYSA-N 0.000 description 9
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 9
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 9
- 101150008656 COL1A1 gene Proteins 0.000 description 9
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 9
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- 239000005642 Oleic acid Substances 0.000 description 9
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 9
- 210000002744 extracellular matrix Anatomy 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 208000006454 hepatitis Diseases 0.000 description 9
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 9
- 238000012317 liver biopsy Methods 0.000 description 9
- 208000019423 liver disease Diseases 0.000 description 9
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 108010028780 Complement C3 Proteins 0.000 description 8
- 102000016918 Complement C3 Human genes 0.000 description 8
- 101000813126 Escherichia coli O157:H7 Laminin-binding fimbrial subunit ElfA Proteins 0.000 description 8
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 8
- 238000013231 NASH rodent model Methods 0.000 description 8
- 230000002411 adverse Effects 0.000 description 8
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical group C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 230000003176 fibrotic effect Effects 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 208000018191 liver inflammation Diseases 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 8
- 238000011830 transgenic mouse model Methods 0.000 description 8
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 7
- 229960001231 choline Drugs 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 229960001519 exenatide Drugs 0.000 description 7
- 230000002641 glycemic effect Effects 0.000 description 7
- 238000003364 immunohistochemistry Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 208000004930 Fatty Liver Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 206010019837 Hepatocellular injury Diseases 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 230000003510 anti-fibrotic effect Effects 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 238000001574 biopsy Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 235000021588 free fatty acids Nutrition 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 150000002926 oxygen Chemical class 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- LYLOCDPEPTYZIQ-KOPIUQRGSA-N (2s)-2-[2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoylamino]-4-methylpentanoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(=O)N[C@H](C(O)=O)CC(C)C LYLOCDPEPTYZIQ-KOPIUQRGSA-N 0.000 description 5
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 5
- 206010019668 Hepatic fibrosis Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000007882 cirrhosis Effects 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002962 histologic effect Effects 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- LUDPTMYCBZDPEZ-JLNKQSITSA-N (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaen-1-ol Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCO LUDPTMYCBZDPEZ-JLNKQSITSA-N 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 4
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 238000011260 co-administration Methods 0.000 description 4
- 239000013066 combination product Substances 0.000 description 4
- 229940127555 combination product Drugs 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- MXUHMQZOATZRIK-UHFFFAOYSA-N methyl 5-amino-2-hydroxybenzoate Chemical compound COC(=O)C1=CC(N)=CC=C1O MXUHMQZOATZRIK-UHFFFAOYSA-N 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 235000009643 reducing diet Nutrition 0.000 description 4
- 238000011808 rodent model Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000013426 sirius red morphometry Methods 0.000 description 4
- RMCFIVUZBILRIV-QXPWYRSVSA-N tert-butyl n-[2-[2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoylamino]ethyl]carbamate Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(=O)NCCNC(=O)OC(C)(C)C RMCFIVUZBILRIV-QXPWYRSVSA-N 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- IWOVFTUTKBEIPL-FBBAKELXSA-N (4s,5r)-3-[(2s)-2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoyl]-4-methyl-5-phenyl-1,3-oxazolidin-2-one Chemical compound O1C(=O)N(C(=O)[C@H](CC)OCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)[C@@H](C)[C@H]1C1=CC=CC=C1 IWOVFTUTKBEIPL-FBBAKELXSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 3
- 102000013918 Apolipoproteins E Human genes 0.000 description 3
- 108010025628 Apolipoproteins E Proteins 0.000 description 3
- UJSPBUZLLGOIQD-GKFVBPDJSA-N C(C\C=C/C\C=C/C\C=C/C\C=C/CC)OC(C(=O)OC(C)(C)C)CC Chemical compound C(C\C=C/C\C=C/C\C=C/C\C=C/CC)OC(C(=O)OC(C)(C)C)CC UJSPBUZLLGOIQD-GKFVBPDJSA-N 0.000 description 3
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 3
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 102100027995 Collagenase 3 Human genes 0.000 description 3
- 108050005238 Collagenase 3 Proteins 0.000 description 3
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 description 3
- 102000051325 Glucagon Human genes 0.000 description 3
- 108060003199 Glucagon Proteins 0.000 description 3
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 3
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 3
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- 102000001214 HSP47 Heat-Shock Proteins Human genes 0.000 description 3
- 108010055039 HSP47 Heat-Shock Proteins Proteins 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 description 3
- 101710183215 Lysyl oxidase homolog 2 Proteins 0.000 description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- 102100040918 Pro-glucagon Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 229960005260 amiodarone Drugs 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 230000003178 anti-diabetic effect Effects 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 238000000889 atomisation Methods 0.000 description 3
- 238000007681 bariatric surgery Methods 0.000 description 3
- 229940014641 bydureon Drugs 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 3
- 239000010779 crude oil Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- NAXNEPHURMISQL-FSAORZJKSA-N ethyl (2s)-2-[2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoylamino]-4-methylpentanoate Chemical compound CCOC(=O)[C@H](CC(C)C)NC(=O)C(CC)OCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC NAXNEPHURMISQL-FSAORZJKSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000003352 fibrogenic effect Effects 0.000 description 3
- 230000002615 fibrolytic effect Effects 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 3
- 229960004666 glucagon Drugs 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 210000000651 myofibroblast Anatomy 0.000 description 3
- ATULPQATBDNKCC-AAQCHOMXSA-N n-(2-aminoethyl)-2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanamide Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(=O)NCCN ATULPQATBDNKCC-AAQCHOMXSA-N 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- LFULEKSKNZEWOE-UHFFFAOYSA-N propanil Chemical compound CCC(=O)NC1=CC=C(Cl)C(Cl)=C1 LFULEKSKNZEWOE-UHFFFAOYSA-N 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- WKFJCENSRDHUHY-LTKCOYKYSA-N (3z,6z,9z,12z)-pentadeca-3,6,9,12-tetraen-1-ol Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CCO WKFJCENSRDHUHY-LTKCOYKYSA-N 0.000 description 2
- IWOVFTUTKBEIPL-CESBDKBESA-N (4s,5r)-3-[(2r)-2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoyl]-4-methyl-5-phenyl-1,3-oxazolidin-2-one Chemical compound O1C(=O)N(C(=O)[C@@H](CC)OCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)[C@@H](C)[C@H]1C1=CC=CC=C1 IWOVFTUTKBEIPL-CESBDKBESA-N 0.000 description 2
- NYBCZSBDKXGAGM-DOFZRALJSA-N (5Z,8Z,11Z,14Z)-icosatetraen-1-ol Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCCO NYBCZSBDKXGAGM-DOFZRALJSA-N 0.000 description 2
- ANWLSJLRFZSJNM-AFSLFLIVSA-N (5Z,8Z,11Z,14Z)-nonadeca-5,8,11,14-tetraen-1-ol Chemical compound CCCC\C=C/C\C=C/C\C=C/C\C=C/CCCCO ANWLSJLRFZSJNM-AFSLFLIVSA-N 0.000 description 2
- VRUYETNZJZSLJU-WVBKPSGCSA-N (5Z,8Z,11Z,14Z,17Z)-nonadeca-5,8,11,14,17-pentaen-1-ol Chemical compound C(CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C)O VRUYETNZJZSLJU-WVBKPSGCSA-N 0.000 description 2
- PKAGPPDFQCMUOR-NEDCVQLASA-N (8Z,11Z,14Z,17Z)-1-(oxan-2-yloxy)icosa-8,11,14,17-tetraen-6-ol Chemical compound O1C(CCCC1)OCCCCCC(C\C=C/C\C=C/C\C=C/C\C=C/CC)O PKAGPPDFQCMUOR-NEDCVQLASA-N 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- UPRZJVCZURIIGG-WMPRHZDHSA-N 2-[(2-acetyloxybenzoyl)amino]ethyl 2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoate Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(=O)OCCNC(=O)C1=CC=CC=C1OC(C)=O UPRZJVCZURIIGG-WMPRHZDHSA-N 0.000 description 2
- SOAKZTQHZYFVMK-QXPWYRSVSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl 2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoate Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(=O)OCCNC(=O)OC(C)(C)C SOAKZTQHZYFVMK-QXPWYRSVSA-N 0.000 description 2
- SJLHDMUFTUOWPS-YNUSHXQLSA-N 2-[(4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoxy]butanoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCOC(CC)C(O)=O SJLHDMUFTUOWPS-YNUSHXQLSA-N 0.000 description 2
- JJBSGIKIKLMNBG-GKFVBPDJSA-N 2-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoxy]butanoic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(O)=O JJBSGIKIKLMNBG-GKFVBPDJSA-N 0.000 description 2
- MKPVEYDUBNIAKZ-AAQCHOMXSA-N 2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]butan-1-ol Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)CO MKPVEYDUBNIAKZ-AAQCHOMXSA-N 0.000 description 2
- LQUZDHCOHWVFFI-AAQCHOMXSA-N 2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]-n-(2-isocyanatoethyl)butanamide Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(=O)NCCN=C=O LQUZDHCOHWVFFI-AAQCHOMXSA-N 0.000 description 2
- CVHLYMIYAVHOQM-JEBPEJKESA-N 2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]propanoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(C)C(O)=O CVHLYMIYAVHOQM-JEBPEJKESA-N 0.000 description 2
- YREBNXIPKURMSG-QNEBEIHSSA-N 2-[(8Z,11Z,14Z)-octadeca-8,11,14,17-tetraenoxy]butanoic acid Chemical compound C(CCCCCC\C=C/C\C=C/C\C=C/CC=C)OC(C(=O)O)CC YREBNXIPKURMSG-QNEBEIHSSA-N 0.000 description 2
- XFYBSPAKXRRSCW-LTKCOYKYSA-N 2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]oxane Chemical compound C(CCCCCC\C=C/C\C=C/C\C=C/C\C=C/CC)OC1OCCCC1 XFYBSPAKXRRSCW-LTKCOYKYSA-N 0.000 description 2
- VEPDZXRUSGOBDO-AFSLFLIVSA-N 2-[(8z,11z,14z,17z)-icosa-8,11,14,17-tetraenoxy]butanoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CCCCCCCOC(CC)C(O)=O VEPDZXRUSGOBDO-AFSLFLIVSA-N 0.000 description 2
- GXYDBVIWWGLMNW-WMPRHZDHSA-N 2-[2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoylamino]ethyl 2-acetyloxybenzoate Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(=O)NCCOC(=O)C1=CC=CC=C1OC(C)=O GXYDBVIWWGLMNW-WMPRHZDHSA-N 0.000 description 2
- HLZIALBLRJXNQN-UHFFFAOYSA-N 3-[tert-butyl(dimethyl)silyl]oxypropane-1,2-diol Chemical compound CC(C)(C)[Si](C)(C)OCC(O)CO HLZIALBLRJXNQN-UHFFFAOYSA-N 0.000 description 2
- VPXVODYVPILPRC-LTKCOYKYSA-N 5,6-DiHETE Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CC(O)C(O)CCCC(O)=O VPXVODYVPILPRC-LTKCOYKYSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 2
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
- 108010018763 Biotin carboxylase Proteins 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- GJOQYAAPYRQUHW-YSTUJMKBSA-N C(CCCCCC\C=C/C\C=C/C\C=C/CC=C)O Chemical compound C(CCCCCC\C=C/C\C=C/C\C=C/CC=C)O GJOQYAAPYRQUHW-YSTUJMKBSA-N 0.000 description 2
- DQFYHNWWGYYTTQ-YOILPLPUSA-N C(CCCCCC\C=C/C\C=C/C\C=C/CC=C)OC(C(=O)OC(C)(C)C)CC Chemical compound C(CCCCCC\C=C/C\C=C/C\C=C/CC=C)OC(C(=O)OC(C)(C)C)CC DQFYHNWWGYYTTQ-YOILPLPUSA-N 0.000 description 2
- XNGGFGHBRUTMOO-YSTUJMKBSA-N C(CCCCCC\C=C/C\C=C/C\C=C/CCC)O Chemical compound C(CCCCCC\C=C/C\C=C/C\C=C/CCC)O XNGGFGHBRUTMOO-YSTUJMKBSA-N 0.000 description 2
- SHYZYUJGOUIYQG-QNEBEIHSSA-N C(CCCCCC\C=C/C\C=C/C\C=C/CCC)OC(C(=O)O)CC Chemical compound C(CCCCCC\C=C/C\C=C/C\C=C/CCC)OC(C(=O)O)CC SHYZYUJGOUIYQG-QNEBEIHSSA-N 0.000 description 2
- YPSNLBXAFUSTLE-AAQCHOMXSA-N C(CCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)OC(C(=O)O)CC Chemical compound C(CCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)OC(C(=O)O)CC YPSNLBXAFUSTLE-AAQCHOMXSA-N 0.000 description 2
- HQEPWMUVJGIQQA-ORZIMQNZSA-N C(CCCC\C=C/C\C=C/C\C=C/CCCCC)OC(C(=O)O)CC Chemical compound C(CCCC\C=C/C\C=C/C\C=C/CCCCC)OC(C(=O)O)CC HQEPWMUVJGIQQA-ORZIMQNZSA-N 0.000 description 2
- RPCBSOLFMCUUSJ-ZKWNWVNESA-N C(CCC\C=C/C\C=C/C\C=C/C\C=C/CCCC)OC(C(=O)O)CC Chemical compound C(CCC\C=C/C\C=C/C\C=C/C\C=C/CCCC)OC(C(=O)O)CC RPCBSOLFMCUUSJ-ZKWNWVNESA-N 0.000 description 2
- OMTCTOWFXRHKBR-KBJITKHMSA-N C(CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)OC(C(=O)O[C@@H](C(=O)O)CC)CC Chemical compound C(CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)OC(C(=O)O[C@@H](C(=O)O)CC)CC OMTCTOWFXRHKBR-KBJITKHMSA-N 0.000 description 2
- WBYGBBOQAVBTGL-ZWGOXYDESA-N C(CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)OC(C(=O)O[C@@H](C(=O)OC(C)(C)C)CC)CC Chemical compound C(CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)OC(C(=O)O[C@@H](C(=O)OC(C)(C)C)CC)CC WBYGBBOQAVBTGL-ZWGOXYDESA-N 0.000 description 2
- WBQHCSWJTSZAPI-AAQCHOMXSA-N C(CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)OC(C(=O)O)CC Chemical compound C(CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)OC(C(=O)O)CC WBQHCSWJTSZAPI-AAQCHOMXSA-N 0.000 description 2
- GTWZPAGNNKUWTJ-VFXVTTCSSA-N CCC(OCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C)C(O)=O Chemical compound CCC(OCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C)C(O)=O GTWZPAGNNKUWTJ-VFXVTTCSSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 239000004381 Choline salt Substances 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 208000009139 Gilbert Disease Diseases 0.000 description 2
- 208000022412 Gilbert syndrome Diseases 0.000 description 2
- 238000013218 HFD mouse model Methods 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 208000018565 Hemochromatosis Diseases 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 2
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 2
- 108010019598 Liraglutide Proteins 0.000 description 2
- 108010075639 MAP Kinase Kinase Kinase 5 Proteins 0.000 description 2
- 102100025136 Macrosialin Human genes 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 238000013234 NASH mouse model Methods 0.000 description 2
- MDMYIEAOBWYFDP-MWJSLFTFSA-N O[C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O)OC(C(CC)OCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)=O)C(=O)O Chemical compound O[C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O)OC(C(CC)OCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)=O)C(=O)O MDMYIEAOBWYFDP-MWJSLFTFSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 description 2
- 102100026858 Protein-lysine 6-oxidase Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102100039314 Rho-associated protein kinase 2 Human genes 0.000 description 2
- 101710088493 Rho-associated protein kinase 2 Proteins 0.000 description 2
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 description 2
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 102000014384 Type C Phospholipases Human genes 0.000 description 2
- 108010079194 Type C Phospholipases Proteins 0.000 description 2
- 208000018839 Wilson disease Diseases 0.000 description 2
- NOUDPBCEONUCOV-FJXQXJEOSA-N [(2s)-1-ethoxy-4-methyl-1-oxopentan-2-yl]azanium;chloride Chemical compound Cl.CCOC(=O)[C@@H](N)CC(C)C NOUDPBCEONUCOV-FJXQXJEOSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- BPYKTIZUTYGOLE-UHFFFAOYSA-N billirubin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(C=C3C(=C(C=C)C(=O)N3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-UHFFFAOYSA-N 0.000 description 2
- 238000010256 biochemical assay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 235000019417 choline salt Nutrition 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 230000002254 contraceptive effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- WPFMMEDVSAHABN-VFXVTTCSSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-nonadeca-5,8,11,14,17-pentaenoate Chemical compound C(CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C)(=O)OCC WPFMMEDVSAHABN-VFXVTTCSSA-N 0.000 description 2
- RWGSLEHAYKJECS-QNEBEIHSSA-N ethyl (8Z,11Z,14Z)-octadeca-8,11,14-trienoate Chemical compound C(CCCCCC\C=C/C\C=C/C\C=C/CCC)(=O)OCC RWGSLEHAYKJECS-QNEBEIHSSA-N 0.000 description 2
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 2
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
- BTWWBXPPRYMBDR-UHFFFAOYSA-N ethyl octadeca-8,11,14-triynoate Chemical compound C(CCCCCCC#CCC#CCC#CCCC)(=O)OCC BTWWBXPPRYMBDR-UHFFFAOYSA-N 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 231100000437 hepatocellular injury Toxicity 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 229960002600 icosapent ethyl Drugs 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 2
- 239000000859 incretin Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 229960002397 linagliptin Drugs 0.000 description 2
- 239000011981 lindlar catalyst Substances 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 229960002701 liraglutide Drugs 0.000 description 2
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- OVEHNNQXLPJPPL-UHFFFAOYSA-N lithium;n-propan-2-ylpropan-2-amine Chemical compound [Li].CC(C)NC(C)C OVEHNNQXLPJPPL-UHFFFAOYSA-N 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- VTNGWEPQIDBLGU-AGRJPVHOSA-N methyl (8Z,11Z,14Z)-octadeca-8,11,14,17-tetraenoate Chemical compound COC(=O)CCCCCC\C=C/C\C=C/C\C=C/CC=C VTNGWEPQIDBLGU-AGRJPVHOSA-N 0.000 description 2
- NAHWIWAADJEIIJ-WMPRHZDHSA-N methyl 2-hydroxy-5-[2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoylamino]benzoate Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(=O)NC1=CC=C(O)C(C(=O)OC)=C1 NAHWIWAADJEIIJ-WMPRHZDHSA-N 0.000 description 2
- QKCWEUZFDJQATI-WMPRHZDHSA-N methyl 2-hydroxy-5-[2-[2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoylamino]ethoxycarbonylamino]benzoate Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(=O)NCCOC(=O)NC1=CC=C(O)C(C(=O)OC)=C1 QKCWEUZFDJQATI-WMPRHZDHSA-N 0.000 description 2
- HNXHYNUTFKZVRT-WMPRHZDHSA-N methyl 2-hydroxy-5-[2-[2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoylamino]ethylcarbamoylamino]benzoate Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(=O)NCCNC(=O)NC1=CC=C(O)C(C(=O)OC)=C1 HNXHYNUTFKZVRT-WMPRHZDHSA-N 0.000 description 2
- UBCCARNSNJRAAN-NDGWTIDWSA-N methyl 2-hydroxy-5-[[(2s)-2-[2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoylamino]-4-methylpentanoyl]amino]benzoate Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(=O)N[C@@H](CC(C)C)C(=O)NC1=CC=C(O)C(C(=O)OC)=C1 UBCCARNSNJRAAN-NDGWTIDWSA-N 0.000 description 2
- VYQSNYSJFCGYHK-UHFFFAOYSA-N methyl non-8-ynoate Chemical compound COC(=O)CCCCCCC#C VYQSNYSJFCGYHK-UHFFFAOYSA-N 0.000 description 2
- QKLVFBHKROYPIC-UHFFFAOYSA-N methyl octadec-17-en-8,11,14-triynoate Chemical compound C(CCCCCCC#CCC#CCC#CCC=C)(=O)OC QKLVFBHKROYPIC-UHFFFAOYSA-N 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- BFUAOFITUXUHLN-AAQCHOMXSA-N n-(2-hydroxyethyl)-2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanamide Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(=O)NCCO BFUAOFITUXUHLN-AAQCHOMXSA-N 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002206 pro-fibrotic effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 2
- 150000003248 quinolines Chemical class 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003463 sulfur Chemical class 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- RWRUQXNCVVMOHI-XEHBGNKPSA-N tert-butyl 2-[(2s)-2-[2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoylamino]-4-methylpentanoyl]oxybenzoate Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(=O)N[C@@H](CC(C)C)C(=O)OC1=CC=CC=C1C(=O)OC(C)(C)C RWRUQXNCVVMOHI-XEHBGNKPSA-N 0.000 description 2
- ZUVMNLKWSMTBFJ-QXPWYRSVSA-N tert-butyl 2-[(4Z,7Z,10Z,13Z,16Z)-nonadeca-4,7,10,13,16-pentaenoxy]butanoate Chemical compound C(CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)OC(C(=O)OC(C)(C)C)CC ZUVMNLKWSMTBFJ-QXPWYRSVSA-N 0.000 description 2
- WYJDBDBEWWHFFX-QXPWYRSVSA-N tert-butyl 2-[2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoyloxy]benzoate Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(=O)OC1=CC=CC=C1C(=O)OC(C)(C)C WYJDBDBEWWHFFX-QXPWYRSVSA-N 0.000 description 2
- QAZYGHLQQPTQAX-UHFFFAOYSA-N tert-butyl 2-hydroxybenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1O QAZYGHLQQPTQAX-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 1
- IXXFZUPTQVDPPK-ZAWHAJPISA-N (1r,2r,4r,6r,7r,8r,10s,13r,14s)-17-[4-[4-(3-aminophenyl)triazol-1-yl]butyl]-7-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-10-fluoro-6-methoxy-2,4,6,8,10,14-hexamethyl-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tet Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@](C)(F)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3N=NC(=C3)C=3C=C(N)C=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O IXXFZUPTQVDPPK-ZAWHAJPISA-N 0.000 description 1
- BMPPQUPZDGJUIC-NEUKSRIFSA-N (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]butanoate Chemical compound C(CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)OC(C(=O)OCC1OC(OC1)(C)C)CC BMPPQUPZDGJUIC-NEUKSRIFSA-N 0.000 description 1
- VOGXDRFFBBLZBT-FRSSMCBVSA-N (2r)-2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCO[C@H](CC)C(O)=O VOGXDRFFBBLZBT-FRSSMCBVSA-N 0.000 description 1
- ZHKNLJLMDFQVHJ-RUZDIDTESA-N (2r)-2-[3-[[1,3-benzoxazol-2-yl-[3-(4-methoxyphenoxy)propyl]amino]methyl]phenoxy]butanoic acid Chemical compound CC[C@H](C(O)=O)OC1=CC=CC(CN(CCCOC=2C=CC(OC)=CC=2)C=2OC3=CC=CC=C3N=2)=C1 ZHKNLJLMDFQVHJ-RUZDIDTESA-N 0.000 description 1
- FGMPLJWBKKVCDB-BYPYZUCNSA-N (2s)-1-hydroxypyrrolidine-2-carboxylic acid Chemical compound ON1CCC[C@H]1C(O)=O FGMPLJWBKKVCDB-BYPYZUCNSA-N 0.000 description 1
- VOGXDRFFBBLZBT-DQINFVRLSA-N (2s)-2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCO[C@@H](CC)C(O)=O VOGXDRFFBBLZBT-DQINFVRLSA-N 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- SCVHJVCATBPIHN-SJCJKPOMSA-N (3s)-3-[[(2s)-2-[[2-(2-tert-butylanilino)-2-oxoacetyl]amino]propanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound N([C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)COC=1C(=C(F)C=C(F)C=1F)F)C(=O)C(=O)NC1=CC=CC=C1C(C)(C)C SCVHJVCATBPIHN-SJCJKPOMSA-N 0.000 description 1
- YBXVSLJMTVYDEL-LTKCOYKYSA-N (3z,6z,9z,12z)-pentadeca-3,6,9,12-tetraenal Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CC=O YBXVSLJMTVYDEL-LTKCOYKYSA-N 0.000 description 1
- PFUBQITXZYMAOH-IBGHGJLCSA-N (4-methoxycyclohexyl)methyl (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]butanoyloxy]oxane-2-carboxylate Chemical compound COC1CCC(CC1)COC(=O)[C@H]1O[C@H]([C@@H]([C@H]([C@@H]1O)O)O)OC(C(CC)OCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)=O PFUBQITXZYMAOH-IBGHGJLCSA-N 0.000 description 1
- DKAKEXWBZISBEE-IEECTRCBSA-N (4-methoxyphenyl)methyl (2S,3S,4S,5R,6R)-3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound O[C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O)O)C(=O)OCC1=CC=C(C=C1)OC DKAKEXWBZISBEE-IEECTRCBSA-N 0.000 description 1
- STAKLRVAEMDYDA-JLNKQSITSA-N (4Z,7Z,10Z,13Z,16Z)-nonadeca-4,7,10,13,16-pentaen-1-ol Chemical compound C(CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)O STAKLRVAEMDYDA-JLNKQSITSA-N 0.000 description 1
- PPIBJOQGAJBQDF-CBAPKCEASA-N (4s,5r)-4-methyl-5-phenyl-1,3-oxazolidin-2-one Chemical compound C[C@@H]1NC(=O)O[C@@H]1C1=CC=CC=C1 PPIBJOQGAJBQDF-CBAPKCEASA-N 0.000 description 1
- ABXNPXZSLCLSEO-KUBAVDMBSA-N (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaen-1-ol Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCO ABXNPXZSLCLSEO-KUBAVDMBSA-N 0.000 description 1
- WFYSUQMCIPGKKK-QNEBEIHSSA-N (6z,9z,12z)-octadeca-6,9,12-trien-1-ol Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCO WFYSUQMCIPGKKK-QNEBEIHSSA-N 0.000 description 1
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- ADTMKZPBOJNHBL-JLNKQSITSA-N (7z,10z,13z,16z,19z)-docosa-7,10,13,16,19-pentaen-1-ol Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCCO ADTMKZPBOJNHBL-JLNKQSITSA-N 0.000 description 1
- JNVIIYVQDUHGAD-LTKCOYKYSA-N (8z,11z,14z,17z)-icosa-8,11,14,17-tetraen-1-ol Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CCCCCCCO JNVIIYVQDUHGAD-LTKCOYKYSA-N 0.000 description 1
- IKYKEVDKGZYRMQ-PDBXOOCHSA-N (9Z,12Z,15Z)-octadecatrien-1-ol Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCO IKYKEVDKGZYRMQ-PDBXOOCHSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- IEZDHXBMQMEENH-AAQCHOMXSA-N 1,3-bis[(2,2,2-trifluoroacetyl)oxy]propan-2-yl 2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]butanoate Chemical compound FC(C(=O)OCC(COC(C(F)(F)F)=O)OC(C(CC)OCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)=O)(F)F IEZDHXBMQMEENH-AAQCHOMXSA-N 0.000 description 1
- HUHSQTFTUYBCNT-AAQCHOMXSA-N 1,3-dihydroxypropan-2-yl 2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoate Chemical class CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(=O)OC(CO)CO HUHSQTFTUYBCNT-AAQCHOMXSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- GJFNRSDCSTVPCJ-UHFFFAOYSA-N 1,8-bis(dimethylamino)naphthalene Chemical compound C1=CC(N(C)C)=C2C(N(C)C)=CC=CC2=C1 GJFNRSDCSTVPCJ-UHFFFAOYSA-N 0.000 description 1
- GQBRZBHEPUQRPL-LJQANCHMSA-N 1-[4-[4-[3-methyl-4-[[(1r)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound O([C@H](C)C=1C=CC=CC=1)C(=O)NC=1C(C)=NOC=1C(C=C1)=CC=C1C(C=C1)=CC=C1C1(C(O)=O)CC1 GQBRZBHEPUQRPL-LJQANCHMSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- OWFVSJHRFRIEAK-UHFFFAOYSA-N 15-hydroxyicosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCC(O)CCCC=CC=CC=CC=CC=CC(O)=O OWFVSJHRFRIEAK-UHFFFAOYSA-N 0.000 description 1
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 description 1
- IXJINSQFBQGWKQ-AAQCHOMXSA-N 2,3-dihydroxypropyl 2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]butanoate Chemical compound C(CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)OC(C(=O)OCC(CO)O)CC IXJINSQFBQGWKQ-AAQCHOMXSA-N 0.000 description 1
- IIYALNBCDFGNNL-UHFFFAOYSA-N 2-(5-bromopentoxy)oxane Chemical compound BrCCCCCOC1CCCCO1 IIYALNBCDFGNNL-UHFFFAOYSA-N 0.000 description 1
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 description 1
- QLGLBUMDIRFCLE-AAQCHOMXSA-N 2-[(2-hydroxybenzoyl)amino]ethyl 2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoate Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(=O)OCCNC(=O)C1=CC=CC=C1O QLGLBUMDIRFCLE-AAQCHOMXSA-N 0.000 description 1
- PKLZTCJBMHHIHQ-LHRCOUKZSA-N 2-[(2s)-2-[2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoylamino]-4-methylpentanoyl]oxybenzoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(=O)N[C@@H](CC(C)C)C(=O)OC1=CC=CC=C1C(O)=O PKLZTCJBMHHIHQ-LHRCOUKZSA-N 0.000 description 1
- CSPATASBAXOKRU-AFSLFLIVSA-N 2-[(3z,6z,9z,12z)-pentadeca-3,6,9,12-tetraenoxy]butanoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CCOC(CC)C(O)=O CSPATASBAXOKRU-AFSLFLIVSA-N 0.000 description 1
- LHGFPXGSRFJCME-AAQCHOMXSA-N 2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]-1-piperidin-1-ylbutan-1-one Chemical compound C(CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)OC(C(=O)N1CCCCC1)CC LHGFPXGSRFJCME-AAQCHOMXSA-N 0.000 description 1
- FFFSECBLIGBLSW-NEUKSRIFSA-N 2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]-N,N-dimethylbutanamide Chemical compound C(CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)OC(C(=O)N(C)C)CC FFFSECBLIGBLSW-NEUKSRIFSA-N 0.000 description 1
- MFAUIWCRLQXUFL-NEUKSRIFSA-N 2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]-N-propan-2-ylbutanamide Chemical compound C(CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)OC(C(=O)NC(C)C)CC MFAUIWCRLQXUFL-NEUKSRIFSA-N 0.000 description 1
- SOOUWWMLLWUBRG-AAQCHOMXSA-N 2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]-2-methylpropanoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(C)(C)C(O)=O SOOUWWMLLWUBRG-AAQCHOMXSA-N 0.000 description 1
- SMMLHZQODOYOJJ-AAQCHOMXSA-N 2-[2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoylamino]ethyl 2-hydroxybenzoate Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(=O)NCCOC(=O)C1=CC=CC=C1O SMMLHZQODOYOJJ-AAQCHOMXSA-N 0.000 description 1
- YSIWGZLTDRBQIL-AAQCHOMXSA-N 2-[2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoylamino]ethyl carbonochloridate Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(=O)NCCOC(Cl)=O YSIWGZLTDRBQIL-AAQCHOMXSA-N 0.000 description 1
- AWZXNEUJVXHPQZ-AAQCHOMXSA-N 2-[2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoyloxy]benzoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(=O)OC1=CC=CC=C1C(O)=O AWZXNEUJVXHPQZ-AAQCHOMXSA-N 0.000 description 1
- KZSKGLFYQAYZCO-UHFFFAOYSA-N 2-[3-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]-3-hydroxyazetidin-1-yl]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC(N2CC(O)(C2)C=2C(=CC(OCC=3C(=NOC=3C3CC3)C=3C(=CC=CC=3Cl)Cl)=CC=2)Cl)=C1 KZSKGLFYQAYZCO-UHFFFAOYSA-N 0.000 description 1
- GKHIVNAUVKXIIY-UHFFFAOYSA-N 2-[3-[4-(1h-indazol-5-ylamino)quinazolin-2-yl]phenoxy]-n-propan-2-ylacetamide Chemical compound CC(C)NC(=O)COC1=CC=CC(C=2N=C3C=CC=CC3=C(NC=3C=C4C=NNC4=CC=3)N=2)=C1 GKHIVNAUVKXIIY-UHFFFAOYSA-N 0.000 description 1
- MXGXUOQOHNPSGF-NEUKSRIFSA-N 2-ethyl-2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)(CC)C(O)=O MXGXUOQOHNPSGF-NEUKSRIFSA-N 0.000 description 1
- JFNAMHYHCCNOIS-NEUKSRIFSA-N 2-ethyl-2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenyl]sulfanylbutanoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCSC(CC)(CC)C(O)=O JFNAMHYHCCNOIS-NEUKSRIFSA-N 0.000 description 1
- RJBUDHLFQYVUGY-AAQCHOMXSA-N 2-hydroxy-5-[2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoylamino]benzoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(=O)NC1=CC=C(O)C(C(O)=O)=C1 RJBUDHLFQYVUGY-AAQCHOMXSA-N 0.000 description 1
- HPTWCHJHXWFGJM-AAQCHOMXSA-N 2-hydroxy-5-[2-[2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoylamino]ethoxycarbonylamino]benzoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(=O)NCCOC(=O)NC1=CC=C(O)C(C(O)=O)=C1 HPTWCHJHXWFGJM-AAQCHOMXSA-N 0.000 description 1
- SWCXGYJGUMVZAB-AAQCHOMXSA-N 2-hydroxy-5-[2-[2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoylamino]ethylcarbamoylamino]benzoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(=O)NCCNC(=O)NC1=CC=C(O)C(C(O)=O)=C1 SWCXGYJGUMVZAB-AAQCHOMXSA-N 0.000 description 1
- VMLWBUFCRRPKFN-GKTRFAQOSA-N 2-hydroxy-5-[[(2s)-2-[2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoylamino]-4-methylpentanoyl]amino]benzoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(=O)N[C@@H](CC(C)C)C(=O)NC1=CC=C(O)C(C(O)=O)=C1 VMLWBUFCRRPKFN-GKTRFAQOSA-N 0.000 description 1
- JNKCXIWJIVUIMN-RXMQYKEDSA-N 2-hydroxy-L-proline Chemical compound OC(=O)[C@]1(O)CCCN1 JNKCXIWJIVUIMN-RXMQYKEDSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- IMOYOUMVYICGCA-UHFFFAOYSA-N 2-tert-butyl-4-hydroxyanisole Chemical compound COC1=CC=C(O)C=C1C(C)(C)C IMOYOUMVYICGCA-UHFFFAOYSA-N 0.000 description 1
- MRBKEAMVRSLQPH-UHFFFAOYSA-N 3-tert-butyl-4-hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1 MRBKEAMVRSLQPH-UHFFFAOYSA-N 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- OQDQIFQRNZIEEJ-UHFFFAOYSA-N 4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloroindol-2-yl]butanoic acid Chemical compound C1=C2N=CSC2=CC(S(=O)(=O)N2C3=CC=C(Cl)C=C3C=C2CCCC(=O)O)=C1 OQDQIFQRNZIEEJ-UHFFFAOYSA-N 0.000 description 1
- XBUXXJUEBFDQHD-UHFFFAOYSA-N 4-[2-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]cyclopropyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1C(C=2C(=CC(OCC=3C(=NOC=3C3CC3)C=3C(=CC=CC=3Cl)Cl)=CC=2)Cl)C1 XBUXXJUEBFDQHD-UHFFFAOYSA-N 0.000 description 1
- APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-O 4-methylmorpholin-4-ium Chemical compound C[NH+]1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-O 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- MJUMOPDYSUMBBI-LTKCOYKYSA-N 6-[(3z,6z,9z,12z)-1-iodopentadeca-3,6,9,12-tetraenyl]oxan-2-one Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CC(I)C1CCCC(=O)O1 MJUMOPDYSUMBBI-LTKCOYKYSA-N 0.000 description 1
- SDDSJMXGJNWMJY-BRHAQHMBSA-N 7-[(2r,4ar,5r,7ar)-2-[(3s)-1,1-difluoro-3-methylpentyl]-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-yl]heptanoic acid Chemical compound O1[C@](C(F)(F)C[C@@H](C)CC)(O)CC[C@@H]2[C@@H](CCCCCCC(O)=O)C(=O)C[C@H]21 SDDSJMXGJNWMJY-BRHAQHMBSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 101710159293 Acyl-CoA desaturase 1 Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010028700 Amine Oxidase (Copper-Containing) Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000011772 Apolipoprotein C-I Human genes 0.000 description 1
- 108010076807 Apolipoprotein C-I Proteins 0.000 description 1
- 102000008128 Apolipoprotein E3 Human genes 0.000 description 1
- 108010060215 Apolipoprotein E3 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BGPFYYKZVSBQMX-WMPRHZDHSA-N C(C)(=O)OCC(CC)OCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC Chemical compound C(C)(=O)OCC(CC)OCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC BGPFYYKZVSBQMX-WMPRHZDHSA-N 0.000 description 1
- HMZOYHSHXIIYEO-QXPWYRSVSA-N C(C)(C)(C)NC(C(CC)OCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)=O Chemical compound C(C)(C)(C)NC(C(CC)OCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)=O HMZOYHSHXIIYEO-QXPWYRSVSA-N 0.000 description 1
- GIHHUPPAJNZRIU-NEUKSRIFSA-N C(C)NC(C(CC)OCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)=O Chemical compound C(C)NC(C(CC)OCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)=O GIHHUPPAJNZRIU-NEUKSRIFSA-N 0.000 description 1
- BOTVKUXEDBZMBY-AAQCHOMXSA-N C(C1=CC=CC=C1)NC(C(CC)OCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)=O Chemical compound C(C1=CC=CC=C1)NC(C(CC)OCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)=O BOTVKUXEDBZMBY-AAQCHOMXSA-N 0.000 description 1
- FGZFOOVJBAZILU-FORXSXPXSA-N C(CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC)OC(C(=O)OC(C)(C)C)CC Chemical compound C(CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC)OC(C(=O)OC(C)(C)C)CC FGZFOOVJBAZILU-FORXSXPXSA-N 0.000 description 1
- ZCZUOPHRPLIALG-WMPRHZDHSA-N C(CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)OC(C(=O)NC)CC Chemical compound C(CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)OC(C(=O)NC)CC ZCZUOPHRPLIALG-WMPRHZDHSA-N 0.000 description 1
- GBPZLLKXNXXFLT-GVMRAPRBSA-N C(CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)O[C@@H](C(=O)N[C@H](C)C1=CC=CC=C1)CC Chemical compound C(CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)O[C@@H](C(=O)N[C@H](C)C1=CC=CC=C1)CC GBPZLLKXNXXFLT-GVMRAPRBSA-N 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- VVXYVYHKNCTWHV-AAQCHOMXSA-N CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(N)=O Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(N)=O VVXYVYHKNCTWHV-AAQCHOMXSA-N 0.000 description 1
- DQJPWIWGHHVIGF-UHFFFAOYSA-N CS(=O)(=O)OCC#CCC#CCC#CCC#CC Chemical compound CS(=O)(=O)OCC#CCC#CCC#CCC#CC DQJPWIWGHHVIGF-UHFFFAOYSA-N 0.000 description 1
- RCNDUHNNXRKYBO-UHFFFAOYSA-N CS(=O)(=O)OCC#CCC#CCC=C Chemical compound CS(=O)(=O)OCC#CCC#CCC=C RCNDUHNNXRKYBO-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 208000004481 Choline Deficiency Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 229920002905 Colesevelam Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102100036869 Diacylglycerol O-acyltransferase 1 Human genes 0.000 description 1
- DVJAMEIQRSHVKC-BDAKNGLRSA-N Dutogliptin Chemical compound OB(O)[C@@H]1CCCN1C(=O)CN[C@H]1CNCC1 DVJAMEIQRSHVKC-BDAKNGLRSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- LCDDAGSJHKEABN-MLGOLLRUSA-N Evogliptin Chemical compound C1CNC(=O)[C@@H](COC(C)(C)C)N1C(=O)C[C@H](N)CC1=CC(F)=C(F)C=C1F LCDDAGSJHKEABN-MLGOLLRUSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000007563 Galectins Human genes 0.000 description 1
- 108010046569 Galectins Proteins 0.000 description 1
- ZWPRRQZNBDYKLH-VIFPVBQESA-N Gemigliptin Chemical compound C([C@@H](N)CC(=O)N1CC2=C(C(=NC(=N2)C(F)(F)F)C(F)(F)F)CC1)N1CC(F)(F)CCC1=O ZWPRRQZNBDYKLH-VIFPVBQESA-N 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- 108010063919 Glucagon Receptors Proteins 0.000 description 1
- 102100040890 Glucagon receptor Human genes 0.000 description 1
- 229940127552 Glucagon-like Peptide-1 (GLP-1) Agonists Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical compound OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 101000928628 Homo sapiens Apolipoprotein C-I Proteins 0.000 description 1
- 101000771674 Homo sapiens Apolipoprotein E Proteins 0.000 description 1
- 101000927974 Homo sapiens Diacylglycerol O-acyltransferase 1 Proteins 0.000 description 1
- 101000608757 Homo sapiens Galectin-3 Proteins 0.000 description 1
- 101001043321 Homo sapiens Lysyl oxidase homolog 1 Proteins 0.000 description 1
- 101001092910 Homo sapiens Serum amyloid P-component Proteins 0.000 description 1
- 101000964713 Homo sapiens Zinc finger protein 395 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 102100021958 Lysyl oxidase homolog 1 Human genes 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 102100027159 Membrane primary amine oxidase Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101150014691 PPARA gene Proteins 0.000 description 1
- 108010089484 PRM-151 Proteins 0.000 description 1
- 101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 description 1
- 108700027412 Pegbelfermin Proteins 0.000 description 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 1
- 229940123263 Phosphodiesterase 3 inhibitor Drugs 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
- 101710164680 Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 108091006269 SLC5A2 Proteins 0.000 description 1
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 1
- 102100036202 Serum amyloid P-component Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- 102000058081 Sodium-Glucose Transporter 2 Human genes 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- KPWYNAGOBXLMSE-UHFFFAOYSA-N Tipelukast Chemical compound CCCC1=C(O)C(C(C)=O)=CC=C1SCCCOC1=CC=C(C(C)=O)C(OCCCC(O)=O)=C1CCC KPWYNAGOBXLMSE-UHFFFAOYSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 229940098113 Transglutaminase inhibitor Drugs 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 102100040733 Zinc finger protein 395 Human genes 0.000 description 1
- DYIHNFRNZLUXTM-VDNBULCGSA-N [3-[2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]butanoyloxy]-2-oxopropyl] 2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]butanoate Chemical compound C(CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)OC(C(=O)OCC(COC(C(CC)OCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)=O)=O)CC DYIHNFRNZLUXTM-VDNBULCGSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 description 1
- 229960004733 albiglutide Drugs 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 229960001667 alogliptin Drugs 0.000 description 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 150000003927 aminopyridines Chemical class 0.000 description 1
- LDXYBEHACFJIEL-HNNXBMFYSA-N anagliptin Chemical compound C=1N2N=C(C)C=C2N=CC=1C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N LDXYBEHACFJIEL-HNNXBMFYSA-N 0.000 description 1
- 229950009977 anagliptin Drugs 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940066595 beta tocopherol Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 1
- UPHHRPQPKDQBSV-UKWJBHCSSA-N butyl 2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]butanoate Chemical compound C(CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)OC(C(=O)OCCCC)CC UPHHRPQPKDQBSV-UKWJBHCSSA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001733 carboxylic acid esters Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229950011033 cenicriviroc Drugs 0.000 description 1
- PNDKCRDVVKJPKG-WHERJAGFSA-N cenicriviroc Chemical compound C1=CC(OCCOCCCC)=CC=C1C1=CC=C(N(CC(C)C)CCC\C(=C/2)C(=O)NC=3C=CC(=CC=3)[S@@](=O)CC=3N(C=NC=3)CCC)C\2=C1 PNDKCRDVVKJPKG-WHERJAGFSA-N 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003467 chloride channel stimulating agent Substances 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 208000021752 choline deficiency disease Diseases 0.000 description 1
- 229940075419 choline hydroxide Drugs 0.000 description 1
- 238000013243 choline-deficient amino acid-defined model Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229950005980 cobiprostone Drugs 0.000 description 1
- 229960001152 colesevelam Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-O diethylammonium Chemical compound CC[NH2+]CC HPNMFZURTQLUMO-UHFFFAOYSA-O 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- UBHZUDXTHNMNLD-UHFFFAOYSA-N dimethylsilane Chemical compound C[SiH2]C UBHZUDXTHNMNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 108010005794 dulaglutide Proteins 0.000 description 1
- 229960005175 dulaglutide Drugs 0.000 description 1
- 229950003693 dutogliptin Drugs 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 229950000234 emricasan Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- SDAXNCQMFACLJX-ZKWNWVNESA-N ethyl (5Z,8Z,11Z,14Z)-nonadeca-5,8,11,14-tetraenoate Chemical compound CCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OCC SDAXNCQMFACLJX-ZKWNWVNESA-N 0.000 description 1
- SNXPWYFWAZVIAU-GKFVBPDJSA-N ethyl arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OCC SNXPWYFWAZVIAU-GKFVBPDJSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- XCUBTXGFDAVUKB-UHFFFAOYSA-N ethyl hex-5-ynoate Chemical compound CCOC(=O)CCCC#C XCUBTXGFDAVUKB-UHFFFAOYSA-N 0.000 description 1
- VQUNQQSFRSCJAO-UHFFFAOYSA-N ethyl non-8-ynoate Chemical compound CCOC(=O)CCCCCCC#C VQUNQQSFRSCJAO-UHFFFAOYSA-N 0.000 description 1
- 230000004090 etiopathogenesis Effects 0.000 description 1
- 229950011259 evogliptin Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229960002458 gemigliptin Drugs 0.000 description 1
- AFLFKFHDSCQHOL-IZZDOVSWSA-N gft505 Chemical compound C1=CC(SC)=CC=C1C(=O)\C=C\C1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1 AFLFKFHDSCQHOL-IZZDOVSWSA-N 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000009716 hepatic expression Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 108700012707 hepatitis C virus NS3 Proteins 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000055379 human APOC1 Human genes 0.000 description 1
- 102000053020 human ApoE Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229950002806 icosabutate Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical class O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 108010004367 lixisenatide Proteins 0.000 description 1
- 229960001093 lixisenatide Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 235000020667 long-chain omega-3 fatty acid Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 101150062900 lpl gene Proteins 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- GNZCSGYHILBXLL-UHFFFAOYSA-N n-tert-butyl-6,7-dichloro-3-methylsulfonylquinoxalin-2-amine Chemical compound ClC1=C(Cl)C=C2N=C(S(C)(=O)=O)C(NC(C)(C)C)=NC2=C1 GNZCSGYHILBXLL-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- AIYYMMQIMJOTBM-UHFFFAOYSA-L nickel(ii) acetate Chemical compound [Ni+2].CC([O-])=O.CC([O-])=O AIYYMMQIMJOTBM-UHFFFAOYSA-L 0.000 description 1
- MKMPWKUAHLTIBJ-ISTRZQFTSA-N omarigliptin Chemical compound C1([C@H]2OC[C@@H](C[C@@H]2N)N2CC3=CN(N=C3C2)S(=O)(=O)C)=CC(F)=CC=C1F MKMPWKUAHLTIBJ-ISTRZQFTSA-N 0.000 description 1
- 229950000074 omarigliptin Drugs 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- SNIUWYYHBQETPM-AAQCHOMXSA-N oxiran-2-ylmethyl 2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]butanoate Chemical compound C(CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)OC(C(=O)OCC1OC1)CC SNIUWYYHBQETPM-AAQCHOMXSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000014306 paracrine signaling Effects 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- CJMKTEIIPMBTJB-DXFHJFHKSA-M potassium;[(2r,3r,4s,5r,6r)-6-[[3-[(3s,4r,5r)-3-butyl-7-(dimethylamino)-3-ethyl-4-hydroxy-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-5-yl]phenyl]carbamoylamino]-3,5-dihydroxy-4-phenylmethoxyoxan-2-yl]methyl sulfate Chemical compound [K+].O([C@H]1[C@H](O)[C@@H](COS([O-])(=O)=O)O[C@H]([C@@H]1O)NC(=O)NC=1C=CC=C(C=1)[C@@H]1C2=CC(=CC=C2S(=O)(=O)C[C@@]([C@@H]1O)(CC)CCCC)N(C)C)CC1=CC=CC=C1 CJMKTEIIPMBTJB-DXFHJFHKSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 108700027806 rGLP-1 Proteins 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 229950011516 remogliflozin etabonate Drugs 0.000 description 1
- UAOCLDQAQNNEAX-ABMICEGHSA-N remogliflozin etabonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O[C@H]1OC1=NN(C(C)C)C(C)=C1CC1=CC=C(OC(C)C)C=C1 UAOCLDQAQNNEAX-ABMICEGHSA-N 0.000 description 1
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229950003181 selonsertib Drugs 0.000 description 1
- YIDDLAAKOYYGJG-UHFFFAOYSA-N selonsertib Chemical compound CC(C)N1C=NN=C1C1=CC=CC(NC(=O)C=2C(=CC(C)=C(C=2)N2C=C(N=C2)C2CC2)F)=N1 YIDDLAAKOYYGJG-UHFFFAOYSA-N 0.000 description 1
- 229950011186 semaglutide Drugs 0.000 description 1
- 108010060325 semaglutide Proteins 0.000 description 1
- 229950009513 simtuzumab Drugs 0.000 description 1
- 238000013424 sirius red staining Methods 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- 108010003524 sodium-bile acid cotransporter Proteins 0.000 description 1
- XGRLSUFHELJJAB-JGSYTFBMSA-M sodium;[(2r)-2-hydroxy-3-[(z)-octadec-9-enoyl]oxypropyl] hydrogen phosphate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)([O-])=O XGRLSUFHELJJAB-JGSYTFBMSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 229950008588 solithromycin Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 description 1
- 108010048573 taspoglutide Proteins 0.000 description 1
- 229950007151 taspoglutide Drugs 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 description 1
- 229950000034 teneligliptin Drugs 0.000 description 1
- GCLOHEFTYUTEJM-QXPWYRSVSA-N tert-butyl 2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]-2-methylpropanoate Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(C)(C)C(=O)OC(C)(C)C GCLOHEFTYUTEJM-QXPWYRSVSA-N 0.000 description 1
- CHSHEVONIHVWMM-QXPWYRSVSA-N tert-butyl 2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoate Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(=O)OC(C)(C)C CHSHEVONIHVWMM-QXPWYRSVSA-N 0.000 description 1
- CUKRZAFVQGOJJK-GKFVBPDJSA-N tert-butyl 2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]butanoate Chemical compound C(C)(C)(C)OC(C(CC)OCCCCCCC\C=C/C\C=C/C\C=C/C\C=C/CC)=O CUKRZAFVQGOJJK-GKFVBPDJSA-N 0.000 description 1
- IGVNJALYNQVQIT-UHFFFAOYSA-N tert-butyl 2-bromo-2-methylpropanoate Chemical compound CC(C)(C)OC(=O)C(C)(C)Br IGVNJALYNQVQIT-UHFFFAOYSA-N 0.000 description 1
- CVAWKJKISIPBOD-UHFFFAOYSA-N tert-butyl 2-bromopropanoate Chemical compound CC(Br)C(=O)OC(C)(C)C CVAWKJKISIPBOD-UHFFFAOYSA-N 0.000 description 1
- QWUIVCRIXAHNFF-RDOWKDNJSA-N tert-butyl 2-ethyl-2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoate Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)(CC)C(=O)OC(C)(C)C QWUIVCRIXAHNFF-RDOWKDNJSA-N 0.000 description 1
- UPRLOYNUXQZAPJ-UHFFFAOYSA-N tert-butyl 2-hydroxybutanoate Chemical compound CCC(O)C(=O)OC(C)(C)C UPRLOYNUXQZAPJ-UHFFFAOYSA-N 0.000 description 1
- CXEMWUYNUIKMNF-UHFFFAOYSA-N tert-butyl 4-chlorosulfonylpiperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(S(Cl)(=O)=O)CC1 CXEMWUYNUIKMNF-UHFFFAOYSA-N 0.000 description 1
- AOCSUUGBCMTKJH-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCN AOCSUUGBCMTKJH-UHFFFAOYSA-N 0.000 description 1
- GPTXCAZYUMDUMN-UHFFFAOYSA-N tert-butyl n-(2-hydroxyethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCO GPTXCAZYUMDUMN-UHFFFAOYSA-N 0.000 description 1
- MKYCOWRYIJJQGD-UHFFFAOYSA-N tert-butyl-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCC1COC(C)(C)O1 MKYCOWRYIJJQGD-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-O tert-butylammonium Chemical compound CC(C)(C)[NH3+] YBRBMKDOPFTVDT-UHFFFAOYSA-O 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229950004996 tipelukast Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010692 trans-unsaturated fatty acids Nutrition 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- IWYJYHUNXVAVAA-OAHLLOKOSA-N trelagliptin Chemical compound C=1C(F)=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 IWYJYHUNXVAVAA-OAHLLOKOSA-N 0.000 description 1
- 229950010728 trelagliptin Drugs 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000011816 wild-type C57Bl6 mouse Methods 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO20171944 | 2017-12-06 | ||
| NO20171945 | 2017-12-06 | ||
| US201862743013P | 2018-10-09 | 2018-10-09 | |
| PCT/IB2018/001459 WO2019111048A1 (en) | 2017-12-06 | 2018-12-05 | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2996688T3 true ES2996688T3 (en) | 2025-02-13 |
Family
ID=65012040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18833289T Active ES2996688T3 (en) | 2017-12-06 | 2018-12-05 | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11925614B2 (https=) |
| EP (1) | EP3720431B1 (https=) |
| JP (2) | JP7346408B2 (https=) |
| KR (1) | KR20200096791A (https=) |
| CN (1) | CN111712240A (https=) |
| AU (2) | AU2018381124B2 (https=) |
| BR (1) | BR112020011431A2 (https=) |
| CA (1) | CA3084728A1 (https=) |
| CL (1) | CL2020001504A1 (https=) |
| ES (1) | ES2996688T3 (https=) |
| HR (1) | HRP20241643T1 (https=) |
| HU (1) | HUE069832T2 (https=) |
| IL (2) | IL308604B2 (https=) |
| MX (1) | MX2020005621A (https=) |
| PH (1) | PH12020550784A1 (https=) |
| PT (1) | PT3720431T (https=) |
| SG (1) | SG11202005007VA (https=) |
| WO (1) | WO2019111048A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2980790T3 (es) | 2015-04-28 | 2024-10-03 | Basf As | Acidos grasos estructuralmente mejorados que contienen azufre para su uso en el tratamiento de la esteatohepatitis no alcohólica |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| JP2020532551A (ja) | 2017-09-03 | 2020-11-12 | アンジオン バイオメディカ コーポレーション | Ｒｈｏ関連コイルドコイルキナーゼ（ＲＯＣＫ）阻害剤としてのビニルヘテロ環 |
| IL308604B2 (en) | 2017-12-06 | 2025-08-01 | Basf As | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| KR20220017917A (ko) | 2019-05-08 | 2022-02-14 | 알리고스 테라퓨틱스 인코포레이티드 | Thr-베타의 조절제 및 이의 사용 방법 |
| CN114470217B (zh) * | 2020-11-24 | 2023-06-20 | 深圳微芯生物科技股份有限公司 | 预防和治疗代谢异常或炎症引起的组织损伤的药物组合物 |
| WO2022137125A1 (en) | 2020-12-22 | 2022-06-30 | Northsea Therapeutics B.V. | Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis |
| MX2023010537A (es) * | 2021-03-08 | 2023-11-28 | Abionyx Pharma Sa | Compuestos útiles para tratar enfermedades del hígado. |
| CN113855812B (zh) * | 2021-12-01 | 2022-03-11 | 上海翰森生物医药科技有限公司 | 聚乙二醇洛塞那肽或其药物组合物的新医药用途 |
| JP2025541481A (ja) | 2022-12-20 | 2025-12-18 | ティーエイチファーム コーポレーション | ナトリウム－グルコース共輸送体－２阻害剤およびアンジオテンシンｉｉ受容体遮断剤を含む非アルコール性脂肪性肝疾患の予防または治療用薬学的組成物 |
| WO2025106728A1 (en) * | 2023-11-14 | 2025-05-22 | The Saban Research Institute; Children's Hospital Los Angeles | Uses of lysophosphatidic acid receptor 1 antagonists |
| WO2025254426A1 (ko) | 2024-06-03 | 2025-12-11 | 주식회사 티에치팜 | 엠파글리플로진 및 텔미사르탄을 함유하는 대사이상 관련 지방성 간질환 예방 또는 치료용 약학적 조성물 |
| KR20250178400A (ko) * | 2024-06-19 | 2025-12-29 | 한국과학기술연구원 | 홍삼박 유래 진토닌을 유효성분으로 포함하는 지방간 질환의 예방, 개선, 또는 치료용 조성물 |
| CN119019255A (zh) * | 2024-08-16 | 2024-11-26 | 合肥工业大学 | 一种dha分子活性探针及其制备方法和应用 |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2909554A (en) | 1956-07-23 | 1959-10-20 | Monsanto Chemicals | Process for the manufacture of (alkylmercapto) alkyl sulfates |
| JPS4839001B1 (https=) | 1970-11-09 | 1973-11-21 | ||
| US4040781A (en) | 1974-06-06 | 1977-08-09 | Lever Brothers Company | Novel 2-(alkylsulfinyl)ethyl sulfates and compositions employing same |
| US4032564A (en) | 1974-09-09 | 1977-06-28 | Zoecon Corporation | Esters of cyclopropylalkanols |
| GB1523276A (en) | 1974-09-20 | 1978-08-31 | Lafon Labor | Sulphur-containing amino compounds |
| US4009211A (en) | 1975-07-29 | 1977-02-22 | Gulf Research & Development Company | Beta,beta-dialkylethylmercaptoethoxylate as new compounds |
| US4209410A (en) | 1976-04-28 | 1980-06-24 | Phillips Petroleum Company | Lubricants |
| DE2861974D1 (en) | 1977-11-11 | 1982-09-16 | Ciba Geigy Ag | Pyridine dicarboxylic acid derivatives, their mixtures with metallic stabilisers and their use in stabilising chlorine-containing thermoplasts |
| JPS5570841A (en) | 1978-11-24 | 1980-05-28 | Konishiroku Photo Ind Co Ltd | Forming method of dye image |
| US4368190A (en) | 1980-04-17 | 1983-01-11 | Merck & Co., Inc. | Immunologically active dipeptidyl 4-O-,6-O-acyl-2-amino-2-deoxy-D-glucose derivatives and methods for their preparation |
| EP0050327B1 (de) | 1980-10-21 | 1984-06-20 | Roche Diagnostics GmbH | Neue schwefelhaltige Phospholipide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US4411808A (en) | 1982-08-04 | 1983-10-25 | Exxon Research & Engineering Co. | Multifunctional additive for power transmission shift fluids |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| US4775223A (en) | 1984-09-20 | 1988-10-04 | Canon Kabushiki Kaisha | Lactic acid derivative, liquid crystal composition containing same and liquid crystal device |
| CA2010000A1 (en) | 1989-04-07 | 1990-10-07 | Paul B. Merkel | Photographic recording material containing a cyan dye-forming coupler |
| JPH0451149A (ja) | 1990-06-19 | 1992-02-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| FR2663928B1 (fr) | 1990-06-27 | 1994-04-08 | Norsolor | Nouveaux composes acryliques soufres, un procede pour leur preparation et leur application a la synthese de nouveaux polymeres. |
| EP0487809A1 (en) | 1990-11-28 | 1992-06-03 | Monsanto Europe S.A./N.V. | Rubber compositions having improved processability and improved rubber-vulcanisate properties |
| CH683149A5 (fr) | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
| JPH0543529A (ja) | 1991-08-10 | 1993-02-23 | Taisho Pharmaceut Co Ltd | アルカンアミドアンモニウム化合物 |
| JP2793458B2 (ja) | 1992-03-19 | 1998-09-03 | 三井化学株式会社 | コネクター用ポリアミド系樹脂組成物およびコネクター |
| JP2755279B2 (ja) | 1992-03-19 | 1998-05-20 | 三井化学株式会社 | 熱可塑性樹脂組成物およびその成形体 |
| CA2164717C (en) | 1993-06-10 | 2009-10-20 | Louis S. Kucera | Method of combatting hepatitis b virus infection |
| JP3110918B2 (ja) | 1993-06-18 | 2000-11-20 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料 |
| US5523430A (en) | 1994-04-14 | 1996-06-04 | Bristol-Myers Squibb Company | Protein farnesyl transferase inhibitors |
| GB2290789B (en) | 1994-07-01 | 1998-09-16 | Ciba Geigy Ag | Titanium and zirconium complexes of carboxylic acids as corrosion inhibitors |
| JPH10507179A (ja) | 1994-10-13 | 1998-07-14 | ペプチド テクノロジー リミテッド | 修飾ポリ不飽和脂肪酸 |
| US7517858B1 (en) | 1995-06-07 | 2009-04-14 | The Regents Of The University Of California | Prodrugs of pharmaceuticals with improved bioavailability |
| FR2741619B1 (fr) | 1995-11-28 | 1998-02-13 | Pf Medicament | Nouveaux derives de 2,3,5-trimethyl-4-hydroxy-anilides, leur preparation et leur application en therapeutique |
| WO1997038688A1 (en) | 1996-04-12 | 1997-10-23 | Peptide Technology Pty. Limited | Methods of treating immunopathologies using polyunsaturated fattyacids |
| US6060515A (en) | 1997-01-24 | 2000-05-09 | The Regents Of The University Of California | Treatment of skin conditions by use of PPARα activators |
| CN1248916A (zh) | 1997-01-24 | 2000-03-29 | 加利福尼亚大学董事会 | FXR、PPARα和LXRα激活剂恢复屏障功能、促进表皮分化和抑制增生的用途 |
| AU4806497A (en) | 1997-10-01 | 1999-04-23 | Procter & Gamble Company, The | Glyoxylic compound comprising one or more active ingredient |
| JPH11180929A (ja) | 1997-12-19 | 1999-07-06 | Asahi Glass Co Ltd | エステル誘導体 |
| WO1999058120A1 (en) | 1998-05-08 | 1999-11-18 | Rolf Berge | USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS |
| FR2786187B1 (fr) | 1998-11-19 | 2001-11-09 | Univ Paris Curie | Composes du type 2-acylamino-2-deoxy-glucono-1,5-lactone, procede d'obtention, compositions les comportant et utilisations |
| FR2792312B1 (fr) | 1999-04-15 | 2001-06-08 | Oreal | Composes (poly)thia-alcynoiques et leurs derives, compositions les comprenant et leur utilisation |
| US6723717B1 (en) | 1999-06-01 | 2004-04-20 | The University Of Texas Southwestern Medical Center | Sulfur-containing thyroxane derivatives and their use as hair growth promotors |
| JP2003500459A (ja) | 1999-06-01 | 2003-01-07 | ザ・ユニバーシティ・オブ・テキサス・サウスウエスタン・メディカル・センター | 置換バイアリールエーテル化合物 |
| AUPQ291499A0 (en) | 1999-09-17 | 1999-10-07 | Women's And Children's Hospital Adelaide | Novel nitro and sulphur containing compounds |
| NO328803B1 (no) | 2000-03-03 | 2010-05-18 | Thia Medica | Nye fettsyreanaloger |
| UA75083C2 (uk) | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Похідні глікопептидфосфонатів |
| FR2828487B1 (fr) | 2001-08-09 | 2005-05-27 | Genfit S A | Nouveaux composes derives d'acides gras, preparation et utilisations |
| JP2005514437A (ja) | 2001-12-21 | 2005-05-19 | スリーエム イノベイティブ プロパティズ カンパニー | イオン対複合体を含む医薬用エアロゾル製剤 |
| GB2383355A (en) | 2001-12-22 | 2003-06-25 | Schlumberger Holdings | An aqueous viscoelastic fluid containing hydrophobically modified polymer and viscoelastic surfactant |
| GB0202002D0 (en) | 2002-01-29 | 2002-03-13 | Leiv Eiriksson Nyotek A S | Use |
| WO2003064707A1 (en) | 2002-01-31 | 2003-08-07 | Tfl Ledertechnik Gmbh | Compositions and its use for imparting water repellency to leather or furskins, textiles and other fibrous materials |
| AU2003251518B2 (en) | 2002-06-13 | 2009-07-02 | New York University | Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
| FR2845991B1 (fr) | 2002-10-16 | 2005-02-04 | Pf Medicament | Derives d'alpha-phenyl acetanilides et leur application en therapeutique humaine |
| US8372430B2 (en) | 2002-12-17 | 2013-02-12 | The Procter & Gamble Company | Compositions, methods, and kits useful for the alleviation of gastrointestinal effects |
| JPWO2004076404A1 (ja) | 2003-02-28 | 2006-06-01 | 株式会社カネカ | ２位に置換基を有する光学活性化合物の製造法 |
| DE10326303A1 (de) | 2003-06-11 | 2004-12-30 | Celares Gmbh | Reagenzien zur Modifikation von Biopharmazeutika, deren Herstellung und Anwendung |
| US20090215895A1 (en) | 2004-01-30 | 2009-08-27 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
| JP4563114B2 (ja) | 2004-08-30 | 2010-10-13 | 出光興産株式会社 | 潤滑剤用添加剤 |
| US20060252670A1 (en) | 2004-10-14 | 2006-11-09 | Intercept Pharmaceuticals Inc. | Method of reducing drug-induced adverse side effects in a patient |
| KR20070108194A (ko) | 2005-03-08 | 2007-11-08 | 시바 스폐셜티 케미칼스 홀딩 인코포레이티드 | 특정 ｎ-아실아미노메틸렌 포스포네이트에 의해 코팅된금속 산화물 나노입자 |
| CN101213281B (zh) | 2005-05-04 | 2013-03-13 | 普罗诺瓦生物医药挪威公司 | 新的dha衍生物及其作为药物的用途 |
| WO2006117668A1 (en) | 2005-05-04 | 2006-11-09 | Pronova Biopharma Norge As | Fatty acid analogues, i.e. dha derivatives for uses as a medicament |
| JP4315134B2 (ja) | 2005-07-06 | 2009-08-19 | セイコーエプソン株式会社 | 電子機器 |
| US20070167529A1 (en) | 2006-01-17 | 2007-07-19 | Walton Rebecca A | Antimicrobial compositions for treating fabrics and surfaces |
| ES2391305T3 (es) | 2006-04-12 | 2012-11-23 | Unilever N.V. | Composición oral que comprende un ácido graso poliinsaturado y ácido salicílico para obtener un efecto antiinflamatorio en la piel |
| EP1849449A1 (en) | 2006-04-26 | 2007-10-31 | 3M Innovative Properties Company | Filler containing composition and process for production and use thereof |
| US7763607B2 (en) | 2006-04-27 | 2010-07-27 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators |
| US20080075692A1 (en) | 2006-05-09 | 2008-03-27 | Perrine Susan P | Methods for treating blood disorders |
| MX2009004337A (es) | 2006-11-01 | 2009-05-22 | Pronova Biopharma Norge As | Compuestos lipidos omega-3. |
| KR101438177B1 (ko) | 2006-11-01 | 2014-09-05 | 프로노바 바이오파마 너지 에이에스 | 페록시솜 증식자-활성화 수용체의 활성자 또는 조절자인 알파-치환된 오메가-3 지질 |
| WO2008053340A1 (en) | 2006-11-03 | 2008-05-08 | Pronova Biopharma Norge As | A combination product comprising at least one lipid substituted in the alpha position and at least one hypoglycemic agent |
| CN101225064A (zh) | 2007-01-19 | 2008-07-23 | 上海汇瑞生物科技有限公司 | 一种制备β-硫杂-α-烷基脂肪酸的新方法 |
| DE102007017179A1 (de) | 2007-04-12 | 2008-10-23 | Clariant International Ltd. | Verfahren zur Herstellung von Alkylpolyglykolcarbonsäuren und Polyglykoldicarbonsäuren mittels Direktoxidation |
| WO2009056983A1 (en) | 2007-10-31 | 2009-05-07 | Pronova Biopharma Norge As | New dha derivatives and their use as medicaments |
| WO2009061208A1 (en) | 2007-11-09 | 2009-05-14 | Pronova Biopharma Norge As | Lipid compounds for use in cosmetic products, as food supplement or as a medicament |
| PE20100156A1 (es) | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| WO2009149496A1 (en) | 2008-06-10 | 2009-12-17 | Central Northern Adelaide Health Service | Treatment of diabetes and complications thereof and related disorders |
| FR2933006B1 (fr) | 2008-06-27 | 2010-08-20 | Inst Francais Du Petrole | Solution absorbante contenant un inhibiteur de degradation soufre a groupement carboxyle et methode pour limiter la degradation d'une solution absorbante |
| DK2315740T3 (en) | 2008-07-08 | 2018-01-08 | Catabasis Pharmaceuticals Inc | Fatty Acid Acetylated Salicylates and Their Uses |
| EP2147910A1 (en) | 2008-07-15 | 2010-01-27 | Pronova BioPharma Norge AS | Novel lipid compounds |
| SG175390A1 (en) * | 2009-04-29 | 2011-12-29 | Amarin Corp Plc | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| BRPI1015120B8 (pt) | 2009-05-08 | 2022-02-15 | Basf As | Composto lipídico alfa-substituídos, derivados de ácidos graxos beta-oxo poli-insaturados, composição farmacêutica e lipídica e métodos para produzir composto lipídico e ácido 2-((5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaeniloxi)butanóico |
| EP2248798A1 (en) | 2009-05-08 | 2010-11-10 | Pronova BioPharma Norge AS | Novel lipid compounds |
| WO2011028689A1 (en) | 2009-09-01 | 2011-03-10 | Catabasis Pharmaceuticals, Inc. | Fatty acid niacin conjugates and their uses |
| EP2526084A1 (en) | 2010-01-20 | 2012-11-28 | Pronova BioPharma Norge AS | Salicylate fatty acid derivatives |
| ES2618604T3 (es) | 2010-11-05 | 2017-06-21 | Pronova Biopharma Norge As | Métodos de tratamiento usando compuestos lipídicos |
| WO2012115695A1 (en) | 2011-02-25 | 2012-08-30 | Catabasis Pharmaceuticals, Inc. | Bis-fatty acid conjugates and their uses |
| WO2014045293A1 (en) | 2012-09-24 | 2014-03-27 | Krisani Bioscience (P) Ltd. | Fatty acid amides with a cysteamine or an acetylated cysteamine group and uses thereof |
| WO2013016531A2 (en) | 2011-07-26 | 2013-01-31 | Purdue Research Foundation | Compounds and methods for use in treating neoplasia and cancer |
| US20130172244A1 (en) | 2011-12-29 | 2013-07-04 | Thomas Klein | Subcutaneous therapeutic use of dpp-4 inhibitor |
| EP2846779A4 (en) | 2012-05-07 | 2015-12-16 | Omthera Pharmaceuticals Inc | STATIN AND OMEGA-3 FATTY ACID COMPOSITIONS |
| US9486433B2 (en) * | 2012-10-12 | 2016-11-08 | Mochida Pharmaceuticals Co. Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| MX377728B (es) * | 2013-02-28 | 2025-03-11 | Pronova Biopharma Norge As | Composición que comprende un compuesto lípido, un triglicerido y un tensioactivo, y métodos de uso de la misma. |
| PL2961727T3 (pl) | 2013-02-28 | 2017-06-30 | Pronova Biopharma Norge As | Sposób wytwarzania kwasu 2-((5Z,8Z, 11Z,14Z,17Z)-ejkoza-5,8,11,14,17-pentaenyloksy)butanowego |
| US9889108B2 (en) * | 2013-03-15 | 2018-02-13 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| US10441560B2 (en) * | 2013-03-15 | 2019-10-15 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| WO2015053379A1 (en) * | 2013-10-07 | 2015-04-16 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| KR102374499B1 (ko) | 2014-04-11 | 2022-03-14 | 사이머베이 쎄라퓨틱스, 인코퍼레이티드 | Nafld 및 nash 의 치료 |
| US9814726B2 (en) * | 2014-04-18 | 2017-11-14 | Lg Chem, Ltd. | Composition for preventing or treating fatty liver diseases |
| KR20180010181A (ko) | 2015-04-01 | 2018-01-30 | 프로노바 바이오파마 너지 에이에스 | Apo c3 의 저하를 위한 티아 옥소 화합물의 용도 |
| ES2980790T3 (es) | 2015-04-28 | 2024-10-03 | Basf As | Acidos grasos estructuralmente mejorados que contienen azufre para su uso en el tratamiento de la esteatohepatitis no alcohólica |
| IL308604B2 (en) * | 2017-12-06 | 2025-08-01 | Basf As | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
-
2018
- 2018-12-05 IL IL308604A patent/IL308604B2/en unknown
- 2018-12-05 ES ES18833289T patent/ES2996688T3/es active Active
- 2018-12-05 KR KR1020207018567A patent/KR20200096791A/ko not_active Ceased
- 2018-12-05 IL IL275002A patent/IL275002B2/en unknown
- 2018-12-05 HR HRP20241643TT patent/HRP20241643T1/hr unknown
- 2018-12-05 PT PT188332894T patent/PT3720431T/pt unknown
- 2018-12-05 CA CA3084728A patent/CA3084728A1/en active Pending
- 2018-12-05 CN CN201880079329.8A patent/CN111712240A/zh active Pending
- 2018-12-05 AU AU2018381124A patent/AU2018381124B2/en active Active
- 2018-12-05 HU HUE18833289A patent/HUE069832T2/hu unknown
- 2018-12-05 US US16/769,659 patent/US11925614B2/en active Active
- 2018-12-05 MX MX2020005621A patent/MX2020005621A/es unknown
- 2018-12-05 PH PH1/2020/550784A patent/PH12020550784A1/en unknown
- 2018-12-05 WO PCT/IB2018/001459 patent/WO2019111048A1/en not_active Ceased
- 2018-12-05 EP EP18833289.4A patent/EP3720431B1/en active Active
- 2018-12-05 SG SG11202005007VA patent/SG11202005007VA/en unknown
- 2018-12-05 BR BR112020011431-6A patent/BR112020011431A2/pt unknown
- 2018-12-05 JP JP2020530675A patent/JP7346408B2/ja active Active
-
2020
- 2020-06-05 CL CL2020001504A patent/CL2020001504A1/es unknown
-
2023
- 2023-09-06 JP JP2023144093A patent/JP7717765B2/ja active Active
-
2024
- 2024-01-22 US US18/418,901 patent/US12440466B2/en active Active
- 2024-09-18 AU AU2024219827A patent/AU2024219827A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20241643T1 (hr) | 2025-02-14 |
| HUE069832T2 (hu) | 2025-04-28 |
| IL275002B2 (en) | 2024-04-01 |
| AU2018381124B2 (en) | 2024-06-27 |
| EP3720431A1 (en) | 2020-10-14 |
| JP2023182579A (ja) | 2023-12-26 |
| JP2021505591A (ja) | 2021-02-18 |
| IL275002A (en) | 2020-07-30 |
| JP7717765B2 (ja) | 2025-08-04 |
| US11925614B2 (en) | 2024-03-12 |
| IL308604A (en) | 2024-01-01 |
| CA3084728A1 (en) | 2019-06-13 |
| AU2024219827A1 (en) | 2024-10-10 |
| EP3720431B1 (en) | 2024-10-30 |
| RU2020122008A (ru) | 2022-01-10 |
| MX2020005621A (es) | 2020-08-20 |
| US20240156769A1 (en) | 2024-05-16 |
| KR20200096791A (ko) | 2020-08-13 |
| BR112020011431A2 (pt) | 2020-11-24 |
| CN111712240A (zh) | 2020-09-25 |
| AU2018381124A1 (en) | 2020-06-04 |
| JP7346408B2 (ja) | 2023-09-19 |
| PT3720431T (pt) | 2024-12-05 |
| WO2019111048A1 (en) | 2019-06-13 |
| US12440466B2 (en) | 2025-10-14 |
| IL308604B1 (en) | 2025-04-01 |
| IL275002B1 (en) | 2023-12-01 |
| US20210177794A1 (en) | 2021-06-17 |
| CL2020001504A1 (es) | 2020-11-13 |
| SG11202005007VA (en) | 2020-06-29 |
| IL308604B2 (en) | 2025-08-01 |
| PH12020550784A1 (en) | 2021-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2996688T3 (en) | Fatty acid derivatives for treating non-alcoholic steatohepatitis | |
| EP2809317A1 (en) | Fatty acids as anti-inflammatory agents | |
| US20200085784A1 (en) | Methods to treat fibrosis, nash, and nafld | |
| CN114286680A (zh) | 肠胃外溶血磷脂酰胆碱制剂诸如lpc-dha、lpc-epa及其在治疗中的用途 | |
| CN106692973A (zh) | 一种组合物及其用途、药物制剂 | |
| RU2705991C2 (ru) | Применение тиаоксосоединений для уменьшения содержания аро с3 | |
| US20200375936A1 (en) | Novel reversible nitroxide derivatives of nitroalkenes that mediate nitrosating and alkylating reactions | |
| RU2820995C2 (ru) | Структурно усиленные жирные кислоты, содержащие кислород, для лечения неалкогольного стеатогепатита | |
| HK40037101B (en) | Fatty acid derivatives for treating non-alcoholic steatohepatitis | |
| HK40037101A (en) | Fatty acid derivatives for treating non-alcoholic steatohepatitis | |
| KR20230128307A (ko) | 비알코올성 지방간염의 치료를 위한 산소-함유 구조적으로개선된 지방산을 포함하는 병용요법 | |
| JP7341916B2 (ja) | アポｃ３を低下させるためのチアオキソ化合物の使用 | |
| CA2886957C (en) | Use of thia oxo compounds for lowering apo c3 | |
| BR102015007435A2 (pt) | uso de compostos tia oxo para diminuir apo c3 |